Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
Launched by BAUSCH & LOMB INCORPORATED · Mar 29, 2019
Trial Information
Current as of June 26, 2025
Completed
Keywords
ClinConnect Summary
The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide dosed three times daily compared with AzoptTM (brinzolamide ophthalmic suspension 1%) dosed three times daily in IOP reduction in patients with POAG or OH.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and females 18 years of age or older,
- • diagnosed with primary open-angle glaucoma or ocular hypertension.
- Exclusion Criteria:
- • Patients with any form of glaucoma (such as secondary, congenital, juvenile or normal tension glaucoma, angle closure glaucoma) in either eye other than primary open-angle glaucoma,
- • ocular hypertension.
About Bausch & Lomb Incorporated
Bausch & Lomb Incorporated is a leading global eye health company dedicated to advancing the vision and well-being of individuals through innovative products and solutions. With a rich history spanning over 160 years, Bausch & Lomb specializes in the development, manufacturing, and marketing of a comprehensive range of eye care products, including contact lenses, lens care solutions, and pharmaceuticals for various ocular conditions. The company is committed to rigorous clinical research and trials to ensure the safety and efficacy of its offerings, striving to enhance patient outcomes and improve quality of life for those with vision-related challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bridgewater, New Jersey, United States
Patients applied
Trial Officials
Lindsey Mathew
Study Director
Bausch Health Americas, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials